The reMARQable Trial Will Study the nMARQ Multielectrode Irrigated Catheter for Treating Paroxysmal Atrial Fibrillation
The reMARQable trial compares the Biosense Webster nMARQ multielectrode catheters to the ThermoCool irrigated catheter for treatment of paroxysmal afib
By Mellanie True Hills and Melissa Moss
June 26, 2014
- Summary: The reMARQable trial will study the nMARQ multielectrode irrigated catheter for treatment of paroxysmal atrial fibrillation
- Reading time: 1–2 minutes
The reMARQable trial, sponsored by Biosense Webster, is studying the nMARQ system employing multiple electrodes on an irrigated catheter. There are two formats — a circular catheter with ten electrodes and a crescent catheter with seven electrodes.
The trial, in patients with symptomatic paroxysmal atrial fibrillation, will compare the nMARQ multi-electrode irrigated catheter to the currently-approved Biosense Webster ThermoCool irrigated catheter.
To learn more about the nMARQ catheter and the reMARQable study, including who is eligible and what centers are participating, see:
- First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ™ Pulmonary Vein Isolation System™ in the Treatment of Paroxysmal Atrial Fibrillation